Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.

Neoplasia · 2022 · PMC8717147 · PMID 34968866

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significancep=0.08so close (0.05 < p ≤ 0.1)

Interestingly, the effect of MDC-22 was significantly more pronounced in male KPC mice (median survival was 150 days for vehicle-treated control versus 199 days for MDC-22 treated mice, log-rank p=0.02), than in female KPC mice, which did not reach statistical significance (median survival was 163 days for vehicle-treated control versus 188 days for MDC-22 treated mice, log-rank p=0.08; Fig. 3 A).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.